Study on Multidrug Resistance of Triple Negative Breast Cancer Cells MDA-MB-23 Mediated by PI3K/Akt/NF-κB Pathway Through P-gp

被引:4
作者
Zhang, Wenjing [1 ]
Song, Bing [1 ]
Yang, Tao [1 ]
机构
[1] Tianjin First Cent Hosp, Dept Gen Surg, Tianjin 300192, Peoples R China
关键词
Breast Cancer; MDR; P-gp; PI3K; NF-kappa B; NF-KAPPA-B; DRUG-RESISTANCE; ACTIVATION; 3-KINASE; THERAPY;
D O I
10.1166/nnl.2018.2794
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Multidrug resistance (MDR) is the dominating obstacle to the chemotherapy. Many studies show that the PI3K signaling pathway is involved in MDR phenotype, however, the mechanism of MDR is still unknown. This study tended to investigate the regulating effect of PI3K/Akt signaling pathway and its downstream target genes in P-gp-mediated MDR in MDA-MB-231/ADR cells. MDA-MB-231/ADR cells were pretreated by PI3K selective inhibitor LY294002 (20 mu mol/L) for 2 h, the sensitivity of ADR was evaluated by the cell counting kit-8 assay, and the expressions of P-gp, LRP, MRP-2, Akt, p-Akt, I kappa B and p-I kappa B were evaluated by Western blot. The activity of ABCB1 promoter was evaluated by CHIP. After inhibiting the activity of PI3K/Akt signaling pathway, the IC50 of ADR decreased from 16.40 +/- 2.41 mu mol/L to 3.60 +/- 0.10 mu mol/L in MDA-MB-231/ADR cells, and RI was 7.20. The expressions of P-gp, p-Akt and p-I kappa B were down-regulated in comparison with that of the control group (P < 0.05), but the expressions of LRP, MRP-2, Akt and I kappa B did not change significantly (P > 0.05). CHIP result has confirmed that NF-kappa B protein could bind to the region of ABCB1 gene promoter in MDA-MB-231/ADR cells. Blocking of PI3K/Akt/NF-kappa B signal pathway could increase the drug sensitivity of MDA-MB-231/ADR cells, inhibit the phosphorylation of p-Akt and p-I kappa B, and reverse MDR of breast cancer cells.
引用
收藏
页码:1441 / 1445
页数:5
相关论文
共 27 条
  • [11] Small-molecule disruptors of glucokinase inhibition
    Linda Koch
    [J]. Nature Reviews Endocrinology, 2014, 10 (2) : 66 - 66
  • [12] Liu H. N., 2011, CHIN J CLIN RATIONAL, V4, P159
  • [13] Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors
    Ma, Cynthia X.
    Crowder, Robert J.
    Ellis, Matthew J.
    [J]. STEROIDS, 2011, 76 (08) : 750 - 752
  • [14] Emerging Role of MicroRNAs in Drug-Resistant Breast Cancer
    Majumder, Sarmila
    Jacob, Samson T.
    [J]. GENE EXPRESSION-THE JOURNAL OF LIVER RESEARCH, 2011, 15 (03): : 141 - 151
  • [15] Meng Z., 2014, WORLD J CLIN ONEOL, V5, P248
  • [16] Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer
    Miller, Todd W.
    Balko, Justin M.
    Arteaga, Carlos L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (33) : 4452 - 4461
  • [17] Biological determinants of endocrine resistance in breast cancer
    Musgrove, Elizabeth A.
    Sutherland, Robert L.
    [J]. NATURE REVIEWS CANCER, 2009, 9 (09) : 631 - 643
  • [18] Evolving Strategies for Overcoming Resistance to HER2-Directed Therapy: Targeting the PI3K/Akt/mTOR Pathway
    Nahta, Rita
    O'Regan, Ruth M.
    [J]. CLINICAL BREAST CANCER, 2010, 10 : S72 - S78
  • [19] Prognostic markers in triple-negative breast cancer
    Rakha, Emad A.
    El-Sayed, Maysa E.
    Green, Andrew R.
    Lee, Andrew H. S.
    Robertson, John F.
    Ellis, Ian O.
    [J]. CANCER, 2007, 109 (01) : 25 - 32
  • [20] Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer
    Sanchez, Cesar G.
    Ma, Cynthia X.
    Crowder, Robert J.
    Guintoli, Therese
    Phommaly, Chanpheng
    Gao, Feng
    Lin, Li
    Ellis, Matthew J.
    [J]. BREAST CANCER RESEARCH, 2011, 13 (02)